

# Anne-Marie Malfait

## List of Publications by Citations

**Source:** <https://exaly.com/author-pdf/7864544/anne-marie-malfait-publications-by-citations.pdf>

**Version:** 2024-04-24

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

72  
papers

3,592  
citations

34  
h-index

59  
g-index

85  
ext. papers

4,187  
ext. citations

5.2  
avg, IF

5.68  
L-index

#	Paper	IF	Citations
72	The role of ADAM-TS4 (aggrecanase-1) and ADAM-TS5 (aggrecanase-2) in a model of cartilage degradation. <i>Osteoarthritis and Cartilage</i> , <b>2001</b> , 9, 539-52	6.2	324
71	Aggrecan degradation in human articular cartilage explants is mediated by both ADAMTS-4 and ADAMTS-5. <i>Arthritis and Rheumatism</i> , <b>2007</b> , 56, 575-85		316
70	Inhibition of ADAM-TS4 and ADAM-TS5 prevents aggrecan degradation in osteoarthritic cartilage. <i>Journal of Biological Chemistry</i> , <b>2002</b> , 277, 22201-8	5.4	230
69	Towards a mechanism-based approach to pain management in osteoarthritis. <i>Nature Reviews Rheumatology</i> , <b>2013</b> , 9, 654-64	8.1	182
68	CCR2 chemokine receptor signaling mediates pain in experimental osteoarthritis. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2012</b> , 109, 20602-7	11.5	167
67	Osteoarthritis joint pain: the cytokine connection. <i>Cytokine</i> , <b>2014</b> , 70, 185-93	4	141
66	ADAMTS-5 deficient mice do not develop mechanical allodynia associated with osteoarthritis following medial meniscal destabilization. <i>Osteoarthritis and Cartilage</i> , <b>2010</b> , 18, 572-80	6.2	99
65	Alpha2-macroglobulin is a novel substrate for ADAMTS-4 and ADAMTS-5 and represents an endogenous inhibitor of these enzymes. <i>Journal of Biological Chemistry</i> , <b>2004</b> , 279, 17554-61	5.4	98
64	Osteoarthritis year in review 2015: biology. <i>Osteoarthritis and Cartilage</i> , <b>2016</b> , 24, 21-6	6.2	96
63	A commentary on modelling osteoarthritis pain in small animals. <i>Osteoarthritis and Cartilage</i> , <b>2013</b> , 21, 1316-26	6.2	96
62	On the predictive utility of animal models of osteoarthritis. <i>Arthritis Research and Therapy</i> , <b>2015</b> , 17, 225-7		89
61	Proprotein convertase furin interacts with and cleaves pro-ADAMTS4 (Aggrecanase-1) in the trans-Golgi network. <i>Journal of Biological Chemistry</i> , <b>2004</b> , 279, 15434-40	5.4	88
60	PCSK6-mediated corin activation is essential for normal blood pressure. <i>Nature Medicine</i> , <b>2015</b> , 21, 1048-55	5.5	83
59	Anti-IL-12 and anti-TNF antibodies synergistically suppress the progression of murine collagen-induced arthritis. <i>European Journal of Immunology</i> , <b>1999</b> , 29, 2205-12	6.1	80
58	Synovial fluid from patients with early osteoarthritis modulates fibroblast-like synoviocyte responses to toll-like receptor 4 and toll-like receptor 2 ligands via soluble CD14. <i>Arthritis and Rheumatism</i> , <b>2012</b> , 64, 2268-77		65
57	ADAMTS-4 (aggrecanase-1): N-terminal activation mechanisms. <i>Archives of Biochemistry and Biophysics</i> , <b>2005</b> , 444, 34-44	4.1	62
56	Damage-associated molecular patterns generated in osteoarthritis directly excite murine nociceptive neurons through Toll-like receptor 4. <i>Arthritis and Rheumatology</i> , <b>2015</b> , 67, 2933-43	9.5	60

55	Proprotein convertase activation of aggrecanases in cartilage in situ. <i>Archives of Biochemistry and Biophysics</i> , <b>2008</b> , 478, 43-51	4.1	59
54	High resolution crystal structure of the catalytic domain of ADAMTS-5 (aggrecanase-2). <i>Journal of Biological Chemistry</i> , <b>2008</b> , 283, 1501-1507	5.4	59
53	A review of the ADAMTS family, pharmaceutical targets of the future. <i>Current Pharmaceutical Design</i> , <b>2009</b> , 15, 2359-74	3.3	58
52	Nanoparticles for improved local retention after intra-articular injection into the knee joint. <i>Pharmaceutical Research</i> , <b>2013</b> , 30, 257-68	4.5	56
51	An aggrecan fragment drives osteoarthritis pain through Toll-like receptor 2. <i>JCI Insight</i> , <b>2018</b> , 3,	9.9	50
50	Therapeutic effects of an anti-ADAMTS-5 antibody on joint damage and mechanical allodynia in a murine model of osteoarthritis. <i>Osteoarthritis and Cartilage</i> , <b>2016</b> , 24, 299-306	6.2	49
49	Structural and inhibition analysis reveals the mechanism of selectivity of a series of aggrecanase inhibitors. <i>Journal of Biological Chemistry</i> , <b>2009</b> , 284, 24185-91	5.4	47
48	Chronic relapsing homologous collagen-induced arthritis in DBA/1 mice as a model for testing disease-modifying and remission-inducing therapies. <i>Arthritis and Rheumatism</i> , <b>2001</b> , 44, 1215-24		44
47	A role for PACE4 in osteoarthritis pain: evidence from human genetic association and null mutant phenotype. <i>Annals of the Rheumatic Diseases</i> , <b>2012</b> , 71, 1042-8	2.4	43
46	Identification of fibronectin neoepitopes present in human osteoarthritic cartilage. <i>Arthritis and Rheumatism</i> , <b>2006</b> , 54, 2912-22		42
45	Nerve growth factor antibody for the treatment of osteoarthritis pain and chronic low-back pain: mechanism of action in the context of efficacy and safety. <i>Pain</i> , <b>2019</b> , 160, 2210-2220	8	41
44	Peripheral Mechanisms Contributing to Osteoarthritis Pain. <i>Current Rheumatology Reports</i> , <b>2018</b> , 20, 9	4.9	39
43	Identification of an ADAMTS-4 cleavage motif using phage display leads to the development of fluorogenic peptide substrates and reveals matrilin-3 as a novel substrate. <i>Journal of Biological Chemistry</i> , <b>2007</b> , 282, 11101-9	5.4	39
42	Emerging Targets for the Management of Osteoarthritis Pain. <i>Current Osteoporosis Reports</i> , <b>2016</b> , 14, 260-268	5.4	38
41	What is new in pain modification in osteoarthritis?. <i>Rheumatology</i> , <b>2018</b> , 57, iv99-iv107	3.9	37
40	ADAM-8 isolated from human osteoarthritic chondrocytes cleaves fibronectin at Ala(271). <i>Arthritis and Rheumatism</i> , <b>2009</b> , 60, 2704-13		36
39	Nerve growth factor blockade for the management of osteoarthritis pain: what can we learn from clinical trials and preclinical models?. <i>Current Opinion in Rheumatology</i> , <b>2017</b> , 29, 110-118	5.3	34
38	Transport and equilibrium uptake of a peptide inhibitor of PACE4 into articular cartilage is dominated by electrostatic interactions. <i>Archives of Biochemistry and Biophysics</i> , <b>2010</b> , 499, 32-9	4.1	33

37	Chemogenetic Inhibition of Pain Neurons in a Mouse Model of Osteoarthritis. <i>Arthritis and Rheumatology</i> , <b>2017</b> , 69, 1429-1439	9.5	31
36	The innate immune response as a mediator of osteoarthritis pain. <i>Osteoarthritis and Cartilage</i> , <b>2020</b> , 28, 562-571	6.2	30
35	Substrate-dependent inhibition kinetics of an active site-directed inhibitor of ADAMTS-4 (Aggrecanase 1). <i>Biochemistry</i> , <b>2007</b> , 46, 6393-401	3.2	29
34	The Role of Peripheral Nociceptive Neurons in the Pathophysiology of Osteoarthritis Pain. <i>Current Osteoporosis Reports</i> , <b>2015</b> , 13, 318-26	5.4	26
33	Will the real aggrecanase(s) step up: evaluating the criteria that define aggrecanase activity in osteoarthritis. <i>Current Pharmaceutical Biotechnology</i> , <b>2008</b> , 9, 16-23	2.6	26
32	Spinal microglial activation in a murine surgical model of knee osteoarthritis. <i>Osteoarthritis and Cartilage</i> , <b>2017</b> , 25, 718-726	6.2	25
31	Genetically Engineered Mouse Models Reveal the Importance of Proteases as Osteoarthritis Drug Targets. <i>Current Rheumatology Reports</i> , <b>2013</b> , 15, 350	4.9	24
30	Visualization of Peripheral Neuron Sensitization in a Surgical Mouse Model of Osteoarthritis by In Vivo Calcium Imaging. <i>Arthritis and Rheumatology</i> , <b>2018</b> , 70, 88-97	9.5	22
29	Osteoarthritis pain: What are we learning from animal models?. <i>Best Practice and Research in Clinical Rheumatology</i> , <b>2017</b> , 31, 676-687	5.3	22
28	Current status of nerve growth factor antibodies for the treatment of osteoarthritis pain. <i>Clinical and Experimental Rheumatology</i> , <b>2017</b> , 35 Suppl 107, 85-87	2.2	22
27	The nociceptive innervation of the normal and osteoarthritic mouse knee. <i>Osteoarthritis and Cartilage</i> , <b>2019</b> , 27, 1669-1679	6.2	21
26	Intra-articular injection of tumor necrosis factor-alpha in the rat: an acute and reversible in vivo model of cartilage proteoglycan degradation. <i>Osteoarthritis and Cartilage</i> , <b>2009</b> , 17, 627-35	6.2	21
25	Standardization of nutrient media for isolated human articular chondrocytes in gelified agarose suspension culture. <i>Osteoarthritis and Cartilage</i> , <b>1995</b> , 3, 249-59	6.2	21
24	Disease Burden in Osteoarthritis Is Similar to That of Rheumatoid Arthritis at Initial Rheumatology Visit and Significantly Greater Six Months Later. <i>Arthritis and Rheumatology</i> , <b>2019</b> , 71, 1276-1284	9.5	20
23	An emerging role for Toll-like receptors at the neuroimmune interface in osteoarthritis. <i>Seminars in Immunopathology</i> , <b>2019</b> , 41, 583-594	12	19
22	Development of a Cartilage Shear-Damage Model to Investigate the Impact of Surface Injury on Chondrocytes and Extracellular Matrix Wear. <i>Cartilage</i> , <b>2017</b> , 8, 444-455	3	14
21	Identification and characterization of UK-201844, a novel inhibitor that interferes with human immunodeficiency virus type 1 gp160 processing. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2007</b> , 51, 3554-61	5.8	14
20	Structure analysis reveals the flexibility of the ADAMTS-5 active site. <i>Protein Science</i> , <b>2011</b> , 20, 735-44	6.3	13

19	Targeting neurotrophic factors: Novel approaches to musculoskeletal pain. <i>Pharmacology &amp; Therapeutics</i> , <b>2020</b> , 211, 107553	13.9	13
18	Chemokine receptor-7 (CCR7) deficiency leads to delayed development of joint damage and functional deficits in a murine model of osteoarthritis. <i>Journal of Orthopaedic Research</i> , <b>2018</b> , 36, 864-875	3.8	10
17	Microarray analyses of the dorsal root ganglia support a role for innate neuro-immune pathways in persistent pain in experimental osteoarthritis. <i>Osteoarthritis and Cartilage</i> , <b>2020</b> , 28, 581-592	6.2	9
16	T cell receptor V beta usage in rheumatoid nodules: marked oligoclonality among IL-2 expanded lymphocytes. <i>Clinical Immunology and Immunopathology</i> , <b>1993</b> , 68, 29-34		8
15	The "elusive DMOAD": Aggrecanase inhibition from laboratory to clinic. <i>Clinical and Experimental Rheumatology</i> , <b>2019</b> , 37 Suppl 120, 130-134	2.2	7
14	Pain-related behaviors and abnormal cutaneous innervation in a murine model of classical Ehlers-Danlos syndrome. <i>Pain</i> , <b>2020</b> , 161, 2274-2283	8	6
13	Neuroimmune interactions and osteoarthritis pain: focus on macrophages. <i>Pain Reports</i> , <b>2021</b> , 6, e892	3.5	6
12	Basic Mechanisms of Pain in Osteoarthritis: Experimental Observations and New Perspectives. <i>Rheumatic Disease Clinics of North America</i> , <b>2021</b> , 47, 165-180	2.4	5
11	A high performance liquid chromatography assay for monitoring proprotein convertase activity. <i>Journal of Chromatography A</i> , <b>2007</b> , 1148, 46-54	4.5	4
10	Size distribution of native aggrecan aggregates of human articular chondrocytes in agarose. <i>In Vitro Cellular and Developmental Biology - Animal</i> , <b>1993</b> , 29A, 356-8	2.6	4
9	The role of intra-articular neuronal CCR2 receptors in knee joint pain associated with experimental osteoarthritis in mice. <i>Arthritis Research and Therapy</i> , <b>2021</b> , 23, 103	5.7	4
8	Animal Models of Ehlers-Danlos Syndromes: Phenotype, Pathogenesis, and Translational Potential. <i>Frontiers in Genetics</i> , <b>2021</b> , 12, 726474	4.5	3
7	The Genesis of Pain in Osteoarthritis: Inflammation as a Mediator of Osteoarthritis Pain.. <i>Clinics in Geriatric Medicine</i> , <b>2022</b> , 38, 221-238	3.8	3
6	Modelling pain in post-traumatic osteoarthritis of the knee. <i>Pain</i> , <b>2012</b> , 153, 257-258	8	2
5	ADAMTS-4 and ADAMTS-5 <b>2005</b> , 299-322		2
4	Pain in the Ehlers-Danlos syndromes: Mechanisms, models, and challenges. <i>American Journal of Medical Genetics, Part C: Seminars in Medical Genetics</i> , <b>2021</b> , 187, 429-445	3.1	2
3	Why we should study pain in animal models of rheumatic diseases. <i>Clinical and Experimental Rheumatology</i> , <b>2017</b> , 35 Suppl 107, 37-39	2.2	2
2	Monoclonal Antibody Therapy in Rheumatoid Arthritis. <i>BioDrugs</i> , <b>1994</b> , 1, 148-156		1

1 Pain in rheumatic diseases. *Clinical and Experimental Rheumatology*, **2017**, 35 Suppl 107, 1

2.2